(Q37868974)

24 August 2017

1 reference

title

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia (English)

1 reference

24 August 2017

1 reference

1 reference

3

Nicola Hardwick

1 reference

24 August 2017

Evelien L J Smits

1

1 reference

24 August 2017

Cindy Lee

2

1 reference

24 August 2017

Suzanne Brooks

4

1 reference

24 August 2017

Viggo F I Van Tendeloo

5

1 reference

24 August 2017

Kim Orchard

6

1 reference

24 August 2017

Barbara-Ann Guinn

7

1 reference

24 August 2017

publication date

26 April 2011

1 reference

Cancer Immunology, Immunotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

60

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

757-769

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1022-6

24 August 2017

exact match

0 references

cites work

Donor lymphocyte infusions for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Reduced-intensity conditioning transplantation in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Immunotherapy of acute myeloid leukemia: current approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Peptide vaccines for patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Activating and inhibitory receptors of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Does chemotherapy modify the immune surveillance of hematological malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

PR1 vaccination in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Recognition of leukaemia cells as foreign before and after autoimmunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Gene-based cancer vaccines: an ex vivo approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Novel non-viral method for transfection of primary leukemia cells and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Tumor vaccines in 2010: need for integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Presentation of tumour antigens by dendritic cells and challenges faced.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Dendritic cell-based cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Proliferating dendritic cell progenitors in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Taking dendritic cells into medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

21 January 2018

Vaccination for leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

T-cell receptor gene transfer for the treatment of leukemia and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Immunotherapy of human cancers using gene modified T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Molecules and mechanisms of the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Determinants of antileukemia effects of allogeneic NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

NK cell receptors and their ligands in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Expansion and activation of natural killer cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The chemokine system in experimental and clinical hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Role of chemokines in the biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Transplantation of anergic histoincompatible bone marrow allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1022-6

10.1007/S00262-011-1022-6

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference